BioAtla, Inc. (BCAB)

BioAtla, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

BioAtla, Inc. (BCAB) is a Biotechnology company based in US with a market capitalization of $5M. Free cash flow was negative at -$48.2M. This page tracks BCAB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 61 employees · IPO Dec 16, 2020

Valuation

Valuation & price

$3.39as of Jul 22, 2026· -94.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

No dividend

Dividend yield

Price — last 12 months

$3.3152-week range$61.00

Loading valuation history…

Fundamentals

Key fundamentals

$5M

Market cap

—

Revenue growth (YoY)

100.0%

Gross margin

-$48.2M

Free cash flow (USD)

-$918K

Net debt

Net cash position

21.1%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

$10.6M$2M

Free cash flow by year

2018 → 2025

-$36.3M-$48.2M

Gross margin by year

2021 → 2025

100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

Insider buys · 90 days

Insider sells · 90 days

Earnings

Last reported: May 15, 2026 (EPS $-6.18)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

8-K eventJul 16, 2026Filing
Annual Meeting Results
Quarterly reportMay 15, 2026Filing
10-Q Filed
Annual reportApr 29, 2026Filing
10-K Filed
8-K eventApr 2, 2026Filing
Merger Announcement
8-K eventMar 31, 2026Filing
Financial Results Reported
Annual reportMar 31, 2026Filing
10-K Filed

Questions

Frequently asked questions

What is BioAtla, Inc.'s market cap?

BioAtla, Inc. (BCAB) has a market capitalization of $5M.

What is BCAB's P/E ratio?

A meaningful P/E ratio is not available for BCAB — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Does BioAtla, Inc. pay a dividend?

No — BCAB did not pay a dividend in its latest reported fiscal year.

When did BioAtla, Inc. last report earnings?

BCAB last reported earnings on May 15, 2026; the next date is not yet scheduled.

Are insiders buying BCAB stock?

SEC Form 4 filings show no open-market insider buys at BioAtla, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

PULM

Pulmatrix, Inc.

$5M

CLGN

CollPlant Biotechnologies Ltd.

$5M

ADXN

Addex Therapeutics Ltd

$5M

APM

Aptorum Group Limited

$5.3M

BRTX

BioRestorative Therapies, Inc.

$4.6M

BCDA

BioCardia, Inc.

$5.5M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.